Comments
Loading...
Adaptimmune Therapeutics Analyst Ratings and Price Targets | NASDAQ:ADAP | Benzinga
Adaptimmune Therapeutics PLC has a consensus price target of $3.36 based on the ratings of 10 analysts. The high is $10 issued by EF Hutton on August 10, 2023. The low is $1 issued by Barclays on August 10, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Guggenheim, and Wells Fargo on April 1, 2025, March 26, 2025, and March 21, 2025, respectively. With an average price target of $2.08 between HC Wainwright & Co., Guggenheim, and Wells Fargo, there's an implied 648.32% upside for Adaptimmune Therapeutics PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Guggenheim
Wells Fargo
Scotiabank
Mizuho
1calculated from analyst ratings
Analyst Ratings for Adaptimmune Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/01/2025 | Buy Now | 977.59% | HC Wainwright & Co. | Arthur He33% | $3.5 → $3 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | 528.59% | Guggenheim | Michael Schmidt57% | $3 → $1.75 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 438.79% | Wells Fargo | Yanan Zhu7% | $2 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | 402.87% | Scotiabank | George Farmer42% | $3.15 → $1.4 | Maintains | Sector Outperform | Get Alert |
| 11/27/2024 | Buy Now | 438.79% | Mizuho | Graig Suvannavejh28% | $3 → $1.5 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 1157.18% | HC Wainwright & Co. | Arthur He33% | $3.5 → $3.5 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 977.59% | Guggenheim | Michael Schmidt57% | $4 → $3 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 1157.18% | HC Wainwright & Co. | Arthur He33% | $4 → $3.5 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 1336.78% | HC Wainwright & Co. | Arthur He33% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 1336.78% | HC Wainwright & Co. | Arthur He33% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 07/30/2024 | Buy Now | 1336.78% | HC Wainwright & Co. | Arthur He33% | → $4 | Initiates | → Buy | Get Alert |
| 05/30/2024 | Buy Now | 1031.47% | Scotiabank | George Farmer42% | → $3.15 | Initiates | → Sector Outperform | Get Alert |
| 05/17/2024 | Buy Now | 977.59% | Mizuho | Graig Suvannavejh28% | $9 → $3 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 259.2% | Barclays | Peter Lawson45% | $2 → $1 | Maintains | Underweight | Get Alert |
| 06/05/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 05/26/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 3491.95% | EF Hutton | Tony Butler15% | → $10 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | 1695.98% | Guggenheim | Michael Schmidt57% | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 11/14/2022 | Buy Now | 977.59% | Wells Fargo | Yanan Zhu7% | $1.5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 3132.76% | Mizuho | Mara Goldstein57% | → $9 | Upgrade | Neutral → Buy | Get Alert |
| 10/04/2022 | Buy Now | 438.79% | Wells Fargo | Nick Abbott19% | $7 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 05/09/2022 | Buy Now | 977.59% | SVB Leerink | Jonathan Chang39% | $2 → $3 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Adaptimmune Therapeutics (ADAP) stock?
The latest price target for Adaptimmune Therapeutics (NASDAQ:ADAP) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $3.00 expecting ADAP to rise to within 12 months (a possible 977.59% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptimmune Therapeutics (ADAP)?
The latest analyst rating for Adaptimmune Therapeutics (NASDAQ:ADAP) was provided by HC Wainwright & Co., and Adaptimmune Therapeutics maintained their buy rating.
When was the last upgrade for Adaptimmune Therapeutics (ADAP)?
The last upgrade for Adaptimmune Therapeutics PLC happened on January 3, 2023 when Guggenheim raised their price target to $5. Guggenheim previously had a neutral for Adaptimmune Therapeutics PLC.
When was the last downgrade for Adaptimmune Therapeutics (ADAP)?
There is no last downgrade for Adaptimmune Therapeutics.
When is the next analyst rating going to be posted or updated for Adaptimmune Therapeutics (ADAP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptimmune Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptimmune Therapeutics was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.
Is the Analyst Rating Adaptimmune Therapeutics (ADAP) correct?
While ratings are subjective and will change, the latest Adaptimmune Therapeutics (ADAP) rating was a maintained with a price target of $3.50 to $3.00. The current price Adaptimmune Therapeutics (ADAP) is trading at is $0.28, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
